2017

These are our stories, our realities


April: Lundbeck leads new EU research project

We bring together companies and universities in a new project supported by the EU that may lead to future treatments of both Parkinson’s disease and Alzheimer’s disease.

March: World class life science

As chair of the Growth Team for Danish Life Science Kåre Schultz has today presented the team’s recommendations for better framework conditions for the industry to the Danish government.

March: Patient groups rank Lundbeck as top tier company

In a worldwide survey, Lundbeck is ranked as number 8 out of 47 pharma companies when it comes to our reputation among patient groups familiar with Lundbeck.

Ferbruary: Exciting breakthrough in antibody research

Leveraging 400 million years of evolution, Lundbeck and biotech company Ossianix has reached an important milestone in our work to use shark antibodies to enable delivery of therapeutic drugs into the brain.

Lundbeck awards Denmark’s most talented young researchers

200 students from upper secondary schools all over Denmark today meet in the final of Lundbeck’s Drughunter natural sciences competition. Minister for Higher Education and Research, Søren Pind, will attend the final, which will be won by the students with the best proposals for research in the treatment of brain diseases.

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.